FDA Approves PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia
Key claim: The FDA approved ropeginterferon alfa-2b (BESREMi) for adults with essential thrombocythemia—the first new ET treatment approval in nearly three decades—regardless of genotype or disease status, including newly diagnosed cytoreductive-naive patients.
Abstract
The FDA approved BESREMi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia, making it the first new FDA-approved treatment for ET in nearly three decades. BESREMi has been approved for adults with ET, regardless of their genotype or disease status, including newly diagnosed patients who are naive to cytoreductive therapy.
Why this matters
This is the first new FDA-approved therapy for ET in nearly three decades and, unlike prior ropeginterferon labeling in PV, the ET indication spans all driver genotypes (JAK2/CALR/MPL/triple-negative) and all disease stages — including cytoreductive-naive patients — repositioning interferon as a frontline option rather than a post-HU salvage. In the ET natural-history frame, this narrows the historical treatment gap between ET and PV and creates a regulatory anchor for the emerging frontline comparisons (e.g., MK-3543-007 bomedemstat vs HU) and NCCN’s recent category 1 designation for interferon in ET.